Kenerson et al(10) demonstrated that tuberous sclerosis complex 1/2 (TSC1/2) inactivation and mTOR hyperactivation were present in non-TSC AMLs and extrarenal PEComas using immunohistochemistry and western blot analysis. The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.